000 | 02405na a2200229 4500 | ||
---|---|---|---|
003 | H12O | ||
005 | 20180417112612.0 | ||
008 | 130622s2012 xxx||||| |||| 00| 0 eng d | ||
040 | _cH12O | ||
041 | _aeng | ||
100 |
_9576 _aMorales Cerdán, José María _eNefrología |
||
245 | 0 | 0 |
_aRenal function and safety in stable kidney transplant recipients converted from immediate-release to prolonged-release tacrolimus. _h[artículo] |
260 |
_bTransplant International, _c2012 |
||
300 | _a25(1):48-55. | ||
500 | _aFormato Vancouver: Lauzurica R, Morales JM, van Hooff J, et al. Renal function and safety in stable kidney transplant recipients converted from immediate-release to prolonged-release tacrolimus. Transpl Int. 2012 Jan;25(1):48-55. | ||
501 | _aPMID: 21992068 | ||
504 | _aContiene 20 referencias | ||
520 | _aThis multicenter, open, phase IIIb study assessed short-term efficacy, safety and dose adjustments in adult stable renal transplant recipients converted from tacrolimus twice-daily (BID) to once-daily (QD). Patients receiving unchanged tacrolimus BID for ≥ 12 weeks were enrolled, and after 6-weeks, converted from tacrolimus BID to QD (morning dose) on a 1 : 1 (mg : mg) total daily dose basis, for a further 12 weeks. Primary endpoint: change in steady-state creatinine clearance between treatment phases. Secondary endpoints: biopsy-proven acute rejection (BPAR), patient and graft survival, safety. 128 patients enrolled (mean age 48.9 years; time post-transplant 48.9 months); 91 evaluated for the primary endpoint. Mean total daily dose was 0.06 mg/kg (BID) and 0.07 mg/kg (QD); 79.1% required one/no dose changes post-conversion to maintain recommended blood-trough levels; average dose increase was small (0.6-0.7 mg/day) with more dose increases in patients on the lowest tacrolimus BID doses. Renal function remained stable and non-inferiority of tacrolimus QD against tacrolimus BID was demonstrated. There were no BPAR episodes; patient and graft survival were 100%. Adverse events were few; none led to dose modifications/discontinuation. Tacrolimus BID to tacrolimus QD conversion is straightforward and does not compromise renal function in stable kidney transplant patients in the short term. | ||
710 |
_986 _aServicio de Nefrología |
||
856 |
_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/6/pc6218.pdf _ySolicitar documento |
||
942 |
_n0 _2ddc _cART |
||
999 |
_c6218 _d6218 |